

***Diagnosis and management of headaches in young people and adults***

**5<sup>th</sup> Guideline Development Group Meeting**

**National Clinical Guideline Centre**

**Date and Time:** ***13<sup>th</sup> May 2011 10:00 – 16:00***

**Place:** *NCGC, 180 Great Portland Street, London*

**GDG Present:** Martin Underwood (Chair)  
Sam Chong  
Carole Gavin  
Devina Halsall  
Kay Kennis  
David Kernick  
Manjit Matharu  
Peter May  
Wendy Thomas

**NCGC Present:** Sara Buckner (morning only)  
Serena Carville  
Zahra Naqvi  
Norma O'Flynn  
Smita Padhi (morning only)  
Tim Reason  
Carlos Sharpin

**Minutes**

1. **Introductions and apologies.** The Chair welcomed everyone to the meeting and noted apologies for Ria Bhola, Brendan Davies, Mark Dunne-Willows, Claire Turner and William Whitehouse.

The GDG were reminded to update their declarations of interest if any changes had occurred since the last meeting. No new declarations of interest were noted.

The minutes of GDG 4 were agreed as an accurate reflection of the meeting, there were no matters arising.

2. **Acute pharmacological treatment of migraine – direct comparisons for intramuscular, intravenous and subcutaneous treatments. (Question 5)**

ZN presented the clinical evidence for the acute pharmacological treatment of migraine with intramuscular, intravenous and subcutaneous treatments. There was no economic evidence to present. The group discussed the evidence and drafted recommendations.

3. **Acute pharmacological treatment of migraine – network meta-analysis for oral, nasal and subcutaneous treatments. (Question 5)**  
SC presented the clinical evidence analysed by network meta-analysis for acute pharmacological treatment of migraine oral, nasal and subcutaneous treatments. The economic evidence is to be presented at GDG 6. The group discussed the evidence and drafted recommendations (pending economic evidence).
4. **Economic Plan.** TR presented the plan for the economic model for acute pharmacological treatment of migraine, updated following teleconference discussions with the economic subgroup. The GDG discussed costs and assumptions of the model.
5. **Protocols for agreement.** The GDG discussed and finalised the remaining protocols for the headaches guideline.
6. **Any other business.** The GDG were informed of the recently held NICE technology appraisal scoping workshop for the use of botulinum toxin in the prophylaxis of chronic migraine. A decision was expected from the department of health in July or August.

**Date, time and venue of the next meeting**

Friday 17<sup>th</sup> June 2011, 10:00–16:00, National Clinical Guidelines Centre, 180 Great Portland Street, London